AegirBio announce the initiation of a clinical study to evaluate saliva based measurements of natalizumab in multiple sclerosis patients. The goal of the study is to confirm that novel saliva calibration method can be used to accurately measure therapeutic drug levels in saliva as compared to blood. The study is being performed in collaboration with Dr. John Foley at the Rocky Mountain MS Clinic in Salt Lake City.

The study is set to run through the next few months and enroll up to 100 patients. The results will be published thereafter. Alongside to the above study, AegirBio also announce that the article "Peptide Mimotope-enabled Quantification of Natalizumab Arm Exchange during Multiple Sclerosis Treatment" has been accepted for publication in the Therapeutic Drug Monitoring journal.

(Page LJ, Lagunas-Acosta J, Heussen R, Castellana ET, Messmer BT. Peptide Mimotope-enabled Quantification of Natalizumab Arm Exchange during Multiple Sclerosis Treatment. Ther Drug Monit.

2022 Oct. 6. doi: 10.1097/FTD.0000000000001038. Epub ahead of print.

PMID: 36201847.).